HCPCS Code C9073
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
| Short Description | Brexucabtagene autoleucel ca |
|---|---|
| Year | 2026 |
| Coverage Code | D = Special coverage instructions apply |
| Action Code | N = No maintenance for this code |
| Action Effective Date | April 01, 2021 |
| Code Added Date | January 01, 2021 |
| Pricing Indicator | 53 = Statute |
| Type of Service | 9 = Other medical items or services F = Ambulatory surgical center (facility usage for surgical services) |
Cross Reference: Q2053